This study suggests that, compared with placebo, individuals with polymyalgia rheumatica receiving 4 mg baricitinib are less likely to need oral glucocorticoids to have low disease activity at week 12 of treatment without any new safety signals.
Click on the article title to read more.
Dr Darrell Menard is a distinguished leader in Canadian sport and exercise medicine, renowned for his exceptional contributions on national and international stages. He has…
Find out what happens during a rheumatoid arthritis flare, how it affects daily life, and patient-approved tips to manage symptoms.
Colchicine for gout flare prophylaxis reduces the risk for cardiovascular events among patients initiating urate-lowering therapy, according to data published in The Lancet Rheumatology. “Cardiovascular…
Objective Determine whether pollutants such as fire smoke-related particulate matter smaller than 2.5 microns (PM2.5) are associated with incident rheumatoid arthritis (RA) and RA-associated interst…
The incidence of musculoskeletal injuries: a systematic review and meta-analysis
Happy New Year, Dear Listener! We’re back for 2025 and have with us Dr. Carol Langford, President of The American College of Rheumatology (ACR) and…
Axial spondyloarthritis manifests as a chronic inflammatory disease primarily affecting the sacroiliac joints and spine. Although chronic back pain and spinal stiffness are typical initial…
